报价延迟最少15分钟:2026/09/08 21:37 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.41 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.09/-0.20
|
|
企业价值
140.49M
|
| 资产负债 |
|
每股账面净值
0.88
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
0.53
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis. |
